BRPI0819220A2 - proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso - Google Patents

proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso

Info

Publication number
BRPI0819220A2
BRPI0819220A2 BRPI0819220-0A BRPI0819220A BRPI0819220A2 BR PI0819220 A2 BRPI0819220 A2 BR PI0819220A2 BR PI0819220 A BRPI0819220 A BR PI0819220A BR PI0819220 A2 BRPI0819220 A2 BR PI0819220A2
Authority
BR
Brazil
Prior art keywords
neurturin
fragment
pharmaceutical composition
neurturin protein
conjugates
Prior art date
Application number
BRPI0819220-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Austen Matthias
Geese Marcus
Mussmann Rainer
Harder Friedrich
Siegmund Thomas
Schneider Martin
Original Assignee
Develogen Aktiengessellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Aktiengessellschaft filed Critical Develogen Aktiengessellschaft
Publication of BRPI0819220A2 publication Critical patent/BRPI0819220A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0819220-0A 2007-11-05 2008-11-05 proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso BRPI0819220A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021493.7 2007-11-05
EP07021493 2007-11-05
PCT/EP2008/009320 WO2009059755A2 (en) 2007-11-05 2008-11-05 Novel neurturin conjugates for pharmaceutical use

Publications (1)

Publication Number Publication Date
BRPI0819220A2 true BRPI0819220A2 (pt) 2019-02-26

Family

ID=40521395

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819220-0A BRPI0819220A2 (pt) 2007-11-05 2008-11-05 proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso

Country Status (17)

Country Link
US (3) US9029323B2 (https=)
EP (1) EP2217282A2 (https=)
JP (2) JP2011503019A (https=)
KR (2) KR20150139982A (https=)
CN (2) CN101848735B (https=)
AU (1) AU2008324426B2 (https=)
BR (1) BRPI0819220A2 (https=)
CA (1) CA2742839A1 (https=)
CO (1) CO6280503A2 (https=)
CR (1) CR11406A (https=)
EA (1) EA201070484A1 (https=)
IL (1) IL205290A (https=)
MX (1) MX2010004899A (https=)
NZ (1) NZ585262A (https=)
SG (1) SG185946A1 (https=)
WO (1) WO2009059755A2 (https=)
ZA (1) ZA201003227B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP4838724B2 (ja) 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
NZ599543A (en) * 2009-10-30 2014-02-28 Ntf Therapeutics Inc Improved neurturin molecules
US8742677B2 (en) * 2010-01-11 2014-06-03 System General Corp. LED drive circuit with a programmable input for LED lighting
CN102453725B (zh) * 2010-11-02 2014-06-11 杭州纽龙生物科技有限公司 一种重组载体、包含该重组载体的重组菌株及制备方法
JP6051378B2 (ja) 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
CA2344277A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
WO2005039643A2 (en) * 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
JP4838724B2 (ja) * 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin

Also Published As

Publication number Publication date
AU2008324426A1 (en) 2009-05-14
US9029323B2 (en) 2015-05-12
AU2008324426B2 (en) 2014-03-27
WO2009059755A2 (en) 2009-05-14
KR20100098619A (ko) 2010-09-08
JP2011503019A (ja) 2011-01-27
WO2009059755A3 (en) 2009-09-24
EP2217282A2 (en) 2010-08-18
CO6280503A2 (es) 2011-05-20
ZA201003227B (en) 2011-03-30
US20160060317A1 (en) 2016-03-03
JP2015057384A (ja) 2015-03-26
KR20150139982A (ko) 2015-12-14
SG185946A1 (en) 2012-12-28
US20110003741A1 (en) 2011-01-06
CN101848735A (zh) 2010-09-29
CN101848735B (zh) 2014-07-23
IL205290A (en) 2014-01-30
IL205290A0 (en) 2010-12-30
CR11406A (es) 2010-10-25
US20130231283A1 (en) 2013-09-05
CN104288775A (zh) 2015-01-21
CA2742839A1 (en) 2009-05-14
EA201070484A1 (ru) 2011-04-29
NZ585262A (en) 2012-06-29
MX2010004899A (es) 2010-09-07

Similar Documents

Publication Publication Date Title
BRPI0819220A2 (pt) proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CL2007002752A1 (es) Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
IL188150A0 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
WO2009099670A3 (en) Oligomer-cannabinoid conjugates
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
EP2078731A4 (en) ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE
BRPI0907650A2 (pt) Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
BRPI0820673A2 (pt) Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal
WO2010021607A3 (en) Pharmaceutical formulation
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
CR10305A (es) "derivados sustituidos de cromanol y su uso.
CR10124A (es) Formulaciones orales que comprenden tigeciclina
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]